If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Distribution agreement

9 Mar 2021 07:00

RNS Number : 5536R
Genedrive PLC
09 March 2021
 

 

 

genedrive plc

("genedrive" or the "Company")

 

Genedrive enters distribution agreement with Mountain Horse Solutions

Distribution of genedrive's Military Assays and Instrument in the United States

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces that it has entered into an agreement for the distribution of the Company's military pathogen detection assays in the United States with Mountain Horse Solutions ("Mountain Horse"), a military contracting specialist to U.S. Federal, State, and Local Government customers.

 

genedrive has a unique product with regard to military CBRNE1 requirements. The Genedrive® BioPlex range of products was developed to the U.S. Department of Defense's (U.S. DoD) product specification with the help of U.S. DoD funding. Designed for field portability and rapid determination of biothreats from pathogens, the Genedrive BioPlex system was developed over a period of five years and has been approved to deployment stage.

 

Contracting with the U.S. Government can be challenging and time consuming. The Company believes that establishing new, local representation in the United States with identified contacts in this highly specialised field will help drive broader product uptake. Organisations like Mountain Horse are already contracted with the U.S. Government, which includes existing framework purchasing agreements, providing an opportunity for more rapid order placement and replenishment of products without the need for new contracts to be negotiated.

 

Bill Allen, President of Mountain Horse Solutions, said: "We are delighted to be working with genedrive with these exciting pathogen detection products. The addition of genedrive's assays to our portfolio of CBRNE mission critical products provides a unique offering of combat-ready sampling and detection devices."

 

David Budd, CEO of genedrive plc, said: "The agreement allows the supply of our BioPlex pathogen detection assays through Mountain Horse, a military contracting specialist who has a number of existing framework contracts with target clients such as the U.S. DoD. We believe that they have both the industry sector knowledge and existing commercial arrangements to increase the exposure of our products and gain new customer opportunities within the various branches and departments of the DoD and U.S. Government."

 

1. Chemical Biological Radiological, Nuclear and Explosive

 

For further details please contact:

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

 

 

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Jackson

 

 

 

finnCap (Joint Broker)

+44 (0)20 7220 0500

Geoff Nash / Kate Bannatyne / Alice Lane

 

 

 

Walbrook PR Ltd (Media & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

 

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

 

About Mountain Horse Solutions 

Mountain Horse Solutions supplies rapid response customized equipment, systems, and training for infectious disease, security, technology, chemical, biological, radiological, nuclear, and explosive (CBRNE) hazards. We specially design innovative solutions, to meet the individual unique threats, needs, and requirements of the military, and first responders. Our team of professionals from around the globe has extensive experience with commercial, DOD, and U.S. Federal Government customers. Mountain Horse Solutions serves organizations, agencies, and contractors worldwide. To find out more visit: www.mtnhorse.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBIGDXBXGDGBI
Date   Source Headline
28th Jan 20219:00 amRNSPrice Monitoring Extension
28th Jan 20217:00 amRNSDistribution agreement with Beckman Coulter
25th Jan 202111:35 amRNSHolding(s) in Company
25th Jan 202111:05 amRNSSecond Price Monitoring Extn
25th Jan 202111:00 amRNSPrice Monitoring Extension
18th Jan 202112:29 pmRNSHolding(s) in Company
18th Jan 20217:00 amRNSNotice of Results
30th Dec 202012:50 pmRNSResult of AGM
23rd Dec 202011:39 amRNSHolding(s) in Company
21st Dec 20202:48 pmRNSResponse to new COVID strain
17th Dec 20209:12 amRNSHolding(s) in Company
16th Dec 20209:05 amRNSSecond Price Monitoring Extn
16th Dec 20209:00 amRNSPrice Monitoring Extension
16th Dec 20207:00 amRNSNotification of intent to distribute in the USA
11th Dec 20207:00 amRNSConversion of Remaining Loan Notes
7th Dec 20207:00 amRNSAdditional Listing
3rd Dec 20207:00 amRNSAIHL hospital study completion
30th Nov 20207:00 amRNSBlock listing Interim Review
26th Nov 20204:41 pmRNSSecond Price Monitoring Extn
26th Nov 20204:35 pmRNSPrice Monitoring Extension
20th Nov 20207:00 amRNSHigh clinical accuracy in India study
17th Nov 20207:00 amRNSFinal Results
10th Nov 202011:05 amRNSSecond Price Monitoring Extn
10th Nov 202011:00 amRNSPrice Monitoring Extension
2nd Nov 20204:40 pmRNSSecond Price Monitoring Extn
2nd Nov 20204:35 pmRNSPrice Monitoring Extension
29th Oct 20207:00 amRNSNotice of Results
28th Oct 20204:41 pmRNSSecond Price Monitoring Extn
28th Oct 20204:36 pmRNSPrice Monitoring Extension
22nd Oct 20207:00 amRNSPoint-of-Care solution to detect SARS-CoV-2 virus
19th Oct 202012:44 pmRNSHolding(s) in Company
12th Oct 202011:18 amRNSHolding(s) in Company
9th Oct 20207:00 amRNSHolding(s) in Company
6th Oct 20207:00 amRNSHolding(s) in Company
1st Oct 20206:09 pmRNSHolding(s) in Company
30th Sep 20207:00 amRNSSouth African approval
28th Sep 20207:00 amRNSPartial Conversion of Loan Notes
25th Sep 20207:00 amRNSVerification with Beckman Coulter Life Sciences
21st Sep 20209:40 amRNSHolding(s) in Company
18th Sep 20202:06 pmRNSSecond Price Monitoring Extn
18th Sep 20202:01 pmRNSPrice Monitoring Extension
17th Sep 20209:27 amRNSHolding(s) in Company
16th Sep 20203:15 pmRNSHolding(s) in Company
16th Sep 20209:00 amRNSHolding(s) in Company
15th Sep 20201:12 pmRNSHolding(s) in Company
14th Sep 20204:40 pmRNSSecond Price Monitoring Extn
14th Sep 20204:35 pmRNSPrice Monitoring Extension
14th Sep 20207:00 amRNSHolding(s) in Company
4th Aug 20202:05 pmRNSSecond Price Monitoring Extn
4th Aug 20202:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.